The economic benefits of risk factor reduction in Canada: Tobacco smoking, excess weight and physical inactivity

Hans Krueger, PhD,^{1,2} Donna Turner, PhD,^{3,4} Joshua Krueger, BA,² A. Elizabeth Ready, PhD⁵

ABSTRACT

OBJECTIVE: Tobacco smoking, excess weight and physical inactivity contribute substantially to the preventable disease burden in Canada. The purpose of this paper is to apply a recently developed approach in addressing the issue of double counting in estimating the combined current economic burden of these risk factors (RFs) and to estimate the economic benefits of long-term RF reduction in Canada.

METHODS: We used an approach based on population attributable fractions (PAF) to estimate the economic burden associated with the various RFs. Sex-specific relative risk and age-/sex-specific prevalence data were used in the modelling when available. Excess weight was modelled as a trichotomous exposure (normal weight, overweight, obese) while tobacco smoking was modelled as a tetrachotomous exposure (non-smoker, light, medium or heavy smoker). All costs are given in constant 2012 Canadian dollars.

RESULTS: The annual economic burden of the RFs of tobacco smoking, excess weight and physical inactivity in Canada are estimated at \$50.3 billion in 2012. Sensitivity analysis suggests a range for the economic burden of \$41.6 to \$58.7 billion. Of the \$50.3 billion, \$21.3 (\$20.0 to \$22.6) billion is attributable to tobacco smoking, \$19.0 (\$13.8 to \$24.0) billion to excess weight and \$10.0 (\$7.8 to \$12.0) billion to physical inactivity. A 1% relative annual reduction in each of the three RFs would result in an \$8.5 billion annual reduction in economic burden by 2031.

CONCLUSION: A modest annual 1% relative reduction in the RFs of tobacco smoking, excess weight and physical inactivity can have a substantial health and economic impact over time at the population level.

KEY WORDS: Economic burden; population attributable fraction; risk factors; tobacco smoking; excess weight; physical inactivity

La traduction du résumé se trouve à la fin de l'article.

Can J Public Health 2014;105(1):e69-e78.

espite years of successful reduction in the prevalence of tobacco smoking,^{1,2} it remains the number one risk factor (RF) with respect to the preventable disease burden in Canada and the United States.^{3,4} Recent trend information from the US suggests a convergence of relative and absolute risk of death from smoking in men and women, resulting from the convergence of smoking patterns between the sexes since the 1960s.⁵ Furthermore, the rate of death from chronic obstructive pulmonary disease (COPD) appears to be increasing in both male and female smokers, possibly due to design changes in cigarettes that promote deeper inhalation of smoke.⁵

Excess weight is second on the list of RFs with respect to the preventable disease burden in Canada and the US,³ and yet this RF continues to increase in prevalence.⁶ Both excess weight and physical inactivity have independently been implicated as RFs for a variety of chronic diseases. Consequently, these RFs have joined tobacco smoking as key prevention targets.

Estimations of the economic burden generated by such RFs have been undertaken in many jurisdictions in the world,⁷ including Canada⁸⁻¹² and several Canadian provinces.^{13,14} In addition to understanding the costs related to a single RF, estimating the aggregate economic burden generated by two or more RFs in a population is often of interest.¹⁵ This information can inform prevention strategies aimed at more than one RF. There are, however, analytical challenges involved with the estimation of the aggregate burden of multiple RFs in a population. Certain costs (e.g., those generated by incident disease or death) are, by definition, accrued only once. Thus, it is important to account for the confounding effect of multiple RFs in the same individual, and specifically to adjust for any increase in the calculated economic burden due to double counting cases and costs.¹⁶

The purpose of this study is twofold: 1) to apply a recently developed approach to address this issue of double counting in estimating the combined economic burden of tobacco smoking, excess weight and physical inactivity in Canada, and 2) to estimate the economic benefits of long-term RF reduction in Canada.¹⁶ This current model has been updated to include economic data for the year 2012, prevalence and relative risk information for tobacco smoking by intensity and a flexible module, which can be used to estimate the economic benefits of long-term RF reduction.

METHODS

The details of our base model have been previously published.¹⁶ In short, we used an approach based on population attributable

Author Affiliations

- 1. School of Population and Public Health, University of British Columbia, Vancouver, BC
- 2. H. Krueger & Associates Inc., Delta, BC

4. CancerCare Manitoba, Winnipeg, MB

Correspondence: Hans Krueger, H. Krueger & Associates Inc., 4554 48B Street, Delta, BC V4K 2R8, Tel: 604-946-5464, E-mail: hans@krueger.ca Conflict of Interest: None to declare.

^{3.} Department of Community Health Sciences, University of Manitoba, Winnipeg, MB

^{5.} Faculty of Kinesiology and Recreation Management, University of Manitoba, Winnipeg, MB

Figure 1. Reduction in risk of mortality after smoking cessation, relative to current smokers, females by cause and by year since smoking cessation



Source: Kenfield et al., Journal of the American Medical Association, 2008.

fraction (PAF) to estimate the economic burden associated with the various RFs. PAF is a statistic that combines two facets of a RF and its impact on disease: relative risk (RR) of the RF in reference to a particular disease, and the prevalence of exposure to the RF in the population of interest.

Relative risk

The sources for the RRs associated with excess weight and physical inactivity remain the same as in the previously published model.^{9,17} The 2013 study on 1.3 million UK women was used as the source for RR data associated with tobacco smoking.² RRs were adjusted for geographic region, age, body mass index (BMI), socio-economic status, current alcohol intake, weekly strenuous physical activity, height, oral contraceptive use, menopausal status and menopausal hormone therapy use. RRs are also presented by three levels of smoking intensity based on the number of cigarettes smoked per day at the time of study recruitment, namely <10, 10-19 or \geq 20.

The relative risk data for excess weight is specific to males and females while the source of RR data for physical inactivity did not make this distinction. An additional review of research for sex variations associated with physical inactivity and the risk of stroke,¹⁸ colon¹⁹ and rectal cancers,²⁰ supported the assumption that there is no significant difference in RR between males and females for this RF. The source of RR data for tobacco smoking is based on females only. Recent information suggests a convergence in RR

between females and males, especially when adjusted for smoking intensity.⁵ Even without adjusting for smoking intensity, Jha and colleagues found no significant differences between the sexes in adjusted hazard ratios for various causes of death in current smokers, including cancers, vascular diseases, respiratory diseases and all causes.¹ We therefore assumed that the RRs by smoking intensity would be the same for males and females by disease category.

The point estimates of the RRs are used for calculations in the base model with the upper and lower bounds of the 95% confidence intervals assessed in a sensitivity analysis.

Risk factor exposure

The other half of a PAF calculation depends on high-quality RF prevalence data.²¹ The analysis of Canada's population exposure to tobacco smoking, physical inactivity and overweight/obesity began with information drawn from the 2010 Canadian Community Health Survey (CCHS). First, overweight and obese individuals were those with a BMI of between 25 kg/m² and 30 kg/m² for overweight and 30 kg/m² or greater for obesity, calculated based on self-reported height and weight. For youth aged 12 to 17, the Cole system of BMI was used to determine overweight and obesity rates.²² Second, tobacco smokers were grouped into light (<10 cigarettes per day), moderate (10-19 per day) and heavy (\geq 20 per day) smokers based on additional details on the average

Light Moderne Henry Occuration							Tobacce	o smok	ing							ш	xcess v	veight				Physi	cal in	activit	Ŀ,
Multic frame Multic frame Formic Multic frame				Light			Mo	lerate			Heav	٧٧			Dverwe	eight			Obesit	ير ا					
	Prevalence of Risk Factor i	n Canada in 2010	Male 8.3%	-	Femal¢ 7.0%		Male .9%	.s E	nale 0%	Ma 6.5	le %	Tem 3.0	ale %	Ma 34.7	le %	Fem. 22.5	ale %	Mal 16.0	e %	Fema 12.8 ^c	le %	Ma 41.1	<u>e</u> %	Fema 47.5%	e %
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			A	ll age			A	ages			Alla	ges			Allag	Jes			All ag	es			All aç	Jes	
Taches, bronchus, lung 122 Taches, bronchus, lung 122 Taches, bronchus, lung 122 Taches, bronchus, lung 123 Taches, bronchus, lung 123 Taches, 133 Taches,	Cancers	ICD-9 Code	RR PA	F RI	A PA	F	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF	RR	PAF
	Trachea, bronchus, lung Lip. oral cavity, pharynx, laryn;	162 × 140-149,160,161	10.83 21.4 2.85 9.6	10.8 % 2.8	3 21.C 5 8.9	% 22.0 % 4.91	3 26.6% 13.6%	22.03	26.2% 12.6%	36.00 3	33.3% : 20.9%	36.00 2 7.20 1	26.5% '2.3%												
Explosions15021771%21771%21771%22917.1%1.007.1%Reneasi137137137137137137137136239239239134137Stornach137137137137136239136239239136137131136 <th< td=""><td>Urinary bladder</td><td>188</td><td>2.68 9.7</td><td>% 2.6</td><td>8 8.9</td><td>% 3.6t</td><td>5 10.8%</td><td>3.66</td><td>9.9%</td><td>3.24</td><td>10.2%</td><td>3.24</td><td>5.4%</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	Urinary bladder	188	2.68 9.7	% 2.6	8 8.9	% 3.6t	5 10.8%	3.66	9.9%	3.24	10.2%	3.24	5.4%												
Pincreat 157 139 53% 237 55% 237 55% 237 55% 237 55% 237 135 132 149 160 71% 160 73% 153 132 149 160 73% 154 132 636 153 132 133 153 133 153 133 153 133 153 133 153 153 153 153 153 153 153 153 153 154 153 154 153 1	Esophagus	150	2.17 7.1	% 2.1	7 6.5	% 2.99	9 8.5%	2.99	7.7%	4.62	15.5%	4.62	8.5%	1.13	4.3%										
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Pancreas	157	1.89 5.5	9% 1.8 27	5.3	% 2.3	7 6.5%	2.37	5.7%	2.66	8.4%	2.66	4.3%					2.29 1	7.1% 1	.60 7	.1%				
with with with with with with with with	Stomach	151	2.6 6/.1	2% I./ %	0.4 C	% Z.U ² % 1.54	4 5.2%	1 56	4.5%	2.20	6.5% 2 2%	2.20	3.2%												
Coloricaticancer 133,154 1.20 1.6% 1.20 1.4% 1.22 1.1% 1.27 1.3 1.6% 1.26 1.3 1.6% 1.3 1.3 1.6% 1.3 1.3 1.6% 1.3 1.3 1.6% 1.3 1.3 1.3 1.3% 1.3 1.3% 1.3 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% 1.3% <th1.3%< th=""> 1.3% <th1.3%< th=""> <t< td=""><td>Live Kidnev. other urinary</td><td>189</td><td>1.42 3.0</td><td>~ 1.4 1.4</td><td>2 2.6</td><td>% 2.28</td><td>5 6.3%</td><td>2.28</td><td>5.5%</td><td>2.56</td><td>8.2%</td><td>2.56</td><td>4.2%</td><td>1.40 1</td><td>0.9%</td><td>1.82 1</td><td>3.4%</td><td>1.82 10</td><td>0.4% 2</td><td>.64 14</td><td>%6</td><td></td><td></td><td></td><td></td></t<></th1.3%<></th1.3%<>	Live Kidnev. other urinary	189	1.42 3.0	~ 1.4 1.4	2 2.6	% 2.28	5 6.3%	2.28	5.5%	2.56	8.2%	2.56	4.2%	1.40 1	0.9%	1.82 1	3.4%	1.82 10	0.4% 2	.64 14	%6				
Breast cancer 1/3, 1/25 0.7% 1.25 0.8% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.13 1.6% 1.23 1.33 3.39 3.39% 3.33 3.39% 3.33 3.39% 3.33 3.39% 1.25 1.38 3.39% 1.26% 1.34 5.29 1.38 5.27% 5.319 1.38 5.39% 1.34 5.39% 1.45 5.6% 1.06 1.38 5.39% 1.25 6.3% 1.36% 1.25 6.3% 1.31 5.0% 1.06 1.34 5.0% 1.00 1.29 1.38 3.39% 1.25 2.39% 1.26% 1.34 2.29 1.38 3.20 2.3% 3.38% 1.25 2.29 1.36% 1.31 2.39% 1.31 1.31 1.37 2.29	Colorectal cancer	153, 154	1.20 1.6	% 1.2	0 1.4	% 1.2	2 1.2%	1.22	1.1%	1.39	2.4%	1.39	1.1%	1.51 1	3.2%	1.45	8.5%	1.95 1	1.6% 1	.66 7	.2% 1	.41	1.4%	.41	6.3%
Postmenopusual breast carcer 173 16% 113 16% Endomerial carcer 179 181 182 33% 32.2 9.3% 32.2 19.3% Ovalar carcer 179 181 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.8% 5.9% 1.27 8.6% 1.27 8.6% 1.6% 1.45 5.6% 1.45 5.6% 1.45 5.6% 1.6% 1.45 5.6% 1.45 5.6% 1.6% 1.45 5.6% 1.6% 1.45 1.56% 1.45 1.56% 1.45 5.6% 1.45 1.56% 1.45 1.56% 1.45 1.56% 1.45 1.6% 1.45 1.6% 1.45 1.6% 1.45 1.45% 1.45 1.6% 1.45 1.46% 1.45 1.45%	Breast cancer	174, 175						1.15	0.7%			1.25	0.8%											.31 1	2.8%
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Postmenopausal breast cance	r 174, 175														1.08	1.7%		-	.13 1	.6%				
Ovalian carcer 118 3.8% 1.28 3.39 Coronary heart diseases 411 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 3.87 12.7% 4.55 1.7% 8.09 12.9% 1.8% 1.77 2.6% 1.15 3.10 18.7% 1.45 5.0% 1.61 1.57 5.0% 1.61 9.5% 1.67 1.57 2.0% 1.61 19.8% 1.7 4.5% 1.15 3.1% 1.57 2.0% 1.61 19.8% 1.7 2.2% 3.87 1.57 2.0% 1.61 1.98 1.7 2.5% 3.81 1.55 3.1% 1.67 1.7 2.7% 3.19 1.1.0% 1.3 2.1% 1.77 2.5% 3.81 1.75 8.1% 1.67 1.77 2.9% 1.67 1.77 2.9% 1.30 1.30 1.30 1.30 1.30	Endometrial cancer	179, 181, 182														1.53	9.3%		(m	.22 19	.3%				
Androwscular Diseases 41 3.87 12.7% 3.87 12.1% 7.18 17.0% 8.09 21.1% 8.09 11.9% 8.09 11.9% 8.09 11.9% 8.09 12.9% 1.8% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.45 15.6% 1.60 19.8% 1.6 1.8% 1.6 1.5% 1.5% 1.60 19.8% 1.6 1.5% 1.5% 1.6% 1.55 2.0% 1.60 19.8% 1.6 1.5% 1.6% 1.3 2.0% 1.6 1.5% 1.6% 1.6% 1.75 2.6% 1.6 1.9% 1.6% 1.6% 1.3% 1.0% 1.3% 1.0% 1.3% 1.0% 1.3% 1.0% 1.3% 1.0% 1.3% 1.0% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6% 1.6%	Ovarian cancer	183														1.18	3.8%		-	.28 3	.3%				
Aortc and lisease 410-414 29 3.387 12.1% 5.18% 5.18 1.2% 5.92 11.8% 5.92 11.9% 1.5 7.0% 1.49 5.6% 1.60 19.8% 1.6 1.8% 5.6% 1.6 19.8% 1.6 1.98% 1.6 1.92 8.5% 1.6 1.91 14.2% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.7% 5.1 2.9% 1.30 11.0% 1.3 11.2% 1.51 2.2% 1.6 1.91 14.2% 5.1 2.7% 5.1 2.9% 1.30 11.0% 1.3 11.00% 1.3 1.91 14.2% 5.1 2.2% 1.8 9.9% 2.42 13.9% 1.30 11.0% 1.3 1.90 11.00% 1.3 17.2 1.2% 1.84 9.9% 2.42 13.9% 1.30 11.0% 1.3 1.2% 0.99 1.91 14.2% 5.1 2.7% 5.1 2.8% 2.09 11.8% 1.3 11.0% 1.3 1.00% 1.3 1.2% 0.90% 1.91 14.2% 5.1 2.4% 1.65 7.3% 1.84 9.9% 2.42 13.9% 1.30 11.0% 1.3 1.00% 1.3 1.00\% 0.19 0.168 0.149 0.168 0.149 0.168 0.149 0.168 0.149 0.168 0.149 0.168 0.149 0.168 0.149 0.168 0.140 0.148 0.148 0.148 0.148 0.148 0.148 0.148 0.148 0.150 0.170 0.169 0.1140 0.148 0.148 0.148 0.148 0.148 0.148 0.148 0.150 0.170 0.	Cardiovascular Diseases			c c	, , , 1	1		r T		000		0000													
Controlity fract (used = 410-41) 2.29 1.34 2.26% 1.38 1.77 2.29 1.35 5.9% 1.69 1.69 1.51 7.0% 1.49 5.6% 1.60 1.98% 1.60<	Communication Among Am Among Among A	441	5.8/ 12./ 7.1015	% 5.8	1.21	% /.li	202 CT .	1.18	11 806	8.09 z	21.1%	8.09 1	0%671	00 1	707 1	1 00	. 707 0	, 7.7	5 707 0	10 10	707	11 31		1 1	202 2
Ventoristic 1.34 2.6% 1.34 2.2% 1.39 2.1% 1.39 1.8% 1.77 2.5% 1.79 1.2% 1.39 2.2% 1.30 1.10% 1.3 1.00% 1.3 1.2% 1.30 1.10% 1.3 1.30% 1.31 2.6% 1.34 2.2% 1.39 2.1% 1.39 1.38 1.00% 1.3 1.2% 1.30%<	CUIVITALY TEALL UISEASE Stroke/carebrovascular disease	410-414, 429 0 430-438	1.11 61.0 7 00 0		4.01 %	.0.4 0%	0 12.7%	00 2	8 40%	2 81 1	17.6%	2 81	6 70%	47.1 23	4.1%	1 15	0.0%0 3.1%	2/1	2 0%0.0 7 0%0 1	01 01. 70 5	60% 1	01 09	, %0% C	- 09	0/00. /
Pulmonary embolism 415.1 1.91 19.0% 1.91 14.2% 3.51 20.2% Congestive heart failure 428 1.28 1.28 1.57 1.28 3.51 20.2% 1.30 11.0% 1.3 Reprotorition 401-405 22.71 27.1% 2.2.71 27.1% 2.2.71 27.1% 2.2 1.28 4.5% 1.65 7.3% 1.30 11.0% 1.3 Reprotorition 401-405 2.2.71 27.1% 3.2.87 27.6% 3.2.87 27.4% 60.49 33.6% 60.49 28.8% 3.0% 7.9% 1.42 8.1% 1.30 11.0% 1.3 Reprotoric ung disease 490-492, 493.2 2.06 5.9% 3.06 7.9% 4.42 8.1% 4.2 8.1% 1.2% 1.30 11.0% 1.3 Reprotoric ung disease 490-492, 433 8.1% 3.148 4.2% 8.1% 2.40 1.4 5.9% 1.43 5.9% 1.50 1.70% 1.5	Venous thromboembolism	415.451-453	1.34 2.6	% 2.7 % 1.3	4 2.2	% 1.35	2.1%	1.39	1.8%	1.77	4.5%	1.77	2.2%	C 7:	0.2.0	<u>.</u>	0/1.0	2	- 0.0.	n t	- 0.0.	- 00-	0/0.	4	0/ 7.7
Congestive heart failure 428 1.79 11.2% 1.78 9.0% 1.79 11.2% 1.78 9.0% Hypertension 401-405 1.405 7.3% 1.84 9.9% 2.42 13.9% 1.30 11.0% 1.3 Hypertension 401-405 2.271 27.1% 22.71 27.0% 3.2.87 27.4% 60.49 33.6% 60.49 33.6% 60.49 33.6% 60.49 33.6% 60.49 28.8% 1.06 1.2% 1.2% 1.3 1.0% 1.30 11.0% 1.3 Respiration 490.492 2.06 6.5% 3.06 7.9% 4.42 14.8% 4.42 8.1% 1.25 5.0% 1.78 8.5% Asthma 493 2.06 6.5% 3.06 7.9% 4.42 14.8% 4.42 8.1% 1.25 5.0% 1.78 8.5% Disbetes Disbetes 250.x0, 250.x2 1.86 2.47 8.1% 2.40 16.1% 3.29 21.0% 6.79% 1.50 17.0% 1.50 17.0% 1.50 17.	Pulmonary embolism	415.1					i							1.91 1	9.0%	1.91 1	4.2%	3.51 2.	2.7% 3	.51 20	.2%				
Hypertension 401-405 1.34 1.28 4.5% 1.65 7.3% 1.84 9.9% 2.42 13.9% 1.30 11.0% 1.3 Respiratory Diseases 400-492, 493.2 22.71 27.0% 32.87 27.4% 60.49 33.6% 60.49 28.8% Chronic lung disease 490-492, 493.2 2.06 6.5% 3.06 7.9% 4.42 14.8% 4.42 8.1% Chronic lung disease 490-486 2.06 5.9% 3.06 7.9% 4.42 14.8% 4.42 8.1% Asthma 493 2.06 6.5% 3.06 7.9% 4.12 1.4% 4.13 6.1% 1.78 8.5% Diabets 1.20 6.1% 1.25 5.0% 1.43 6.1% 1.50 17.0% 1.5 Type 2 diabetes 250.x0, 250.x2 1.86 4.6% 1.86 3.9% 2.17 6.1% 2.15 3.3% 2.40 1.50 17.0% 1.50 17.0% 1.50 17.0% 1.50 17.0% 1.50 17.0% 1.50 17.0% <	Congestive heart failure	428																1.79 1	1.2% 1	.78 9	%0.				
Respiratory Diseases 490-492, 493.2 22.71 27.1% 22.71 27.0% 32.87 27.4% 60.49 33.6% 60.49 28.8% Chronic lung disease 490-492, 493.2 2.2.71 27.0% 32.87 27.4% 60.49 28.8% Chronic lung disease 490-492, 493.2 2.06 6.5% 2.06 5.9% 3.06 7.9% 4.42 14.8% 4.42 8.1% Astma 493 2.06 6.5% 2.06 5.9% 3.06 7.9% 4.42 14.8% 4.42 8.1% Astma 493 2.06 6.5% 2.06 8.8% 3.06 7.9% 4.42 14.8% 4.42 8.1% Astma 493 2.0 5.9% 2.06 1.28 3.0% 1.78 8.5% Diabetes 250.x0, 250.x2 1.86 4.6% 1.86 3.9% 2.17 5.3% 2.40 16.1% 3.9 4.50 15.0% 1.5 1.5% 1.5 0.10%	Hypertension	401-405												1.28	4.5%	1.65	7.3%	1.84	9.9% 2	.42 13	.9% 1	.30 11	. %0.	.30 1	2.5%
Chronic lung disease 400-492, 493.2 22.71 27.1% 22.71 27.0% 32.87 27.6% 32.87 27.4% 60.49 33.6% 60.49 28.8% Armonia, influenza 480-486 2.06 6.5% 2.06 5.9% 3.06 8.8% 3.06 7.9% 4.42 14.8% 4.42 8.1% 1.20 6.1% 1.25 5.0% 1.43 6.1% 1.78 8.5% Armonia to the second state and second state and the second state a	Respiratory Diseases																								
Arteuntonia, intractiza 403 5.0% 1.43 6.1% 1.78 8.5% Arteuntonia, intractiza 403 4.1% 1.78 8.5% Arteuntonia, intractiza 403 4.1% 1.78 8.5% Diabetes 403 4.0% 1.6 1.0% 1.5 5.0% 1.43 6.1% 1.78 8.5% Diabetes 250.x0, 250.x2 2.50.x2 2.50.x2 2.50.x2 2.50.x1 4.3.9% 1.50 17.0% 1.5 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%	Chronic lung disease	490-492, 493.2	22.71 27.1	% 22.7	1 27.C 6 5 0	0% 32.8) 0% 2.8	27.6%	32.87	27.4% 7.0%	60.49 0 1 1 2 1	33.6% t	50.49 <i>;</i>	28.8% o 10%												
Diabetes 250.x0, 250.x2 1.86 4.6% 1.86 3.9% 2.17 6.7% 2.17 3.3% 2.40 16.1% 3.92 21.0% 6.74 35.4% 12.41 43.9% 1.50 17.0% 1.5 Urber 2 clabetes 250.x0, 250.x0, 250.x2 2.3.5,.6,.9 2.73 9.1% 3.34 9.6% 3.34 8.7% 3.97 12.8% 3.97 6.9% 1.44 5.2% 1.43 5.7% 2.32 13.4% Carlo disease 571.0, 11, 2,.3,.5,.6,.9 2.73 9.1% 3.34 9.6% 3.34 8.7% 3.97 12.8% 3.97 6.9% 1.44 5.2% 1.43 5.7% 2.32 13.4% 1.59 19.5% 1.5 Carlo disease 574, 575 2.79% 1.96 9.7% 1.59 19.5% 1.5 Croncibactor disease 574, 575 2.74 5.0% 1.96 9.7% 1.59 19.5% 1.5 Croncibactor disease 574, 575 2.74 1.96 9.7% 1.59 19.5% 1.5 Croncibactor disease 5.74, 575 2.74 1.96 9.7% 1.59 19.5% 1.5 Croncibactor disease 5.74, 575 2.74 1.96 9.7% 1.59 19.5% 1.5 Croncibactor disease 5.74 1.50 1.56 1.56 1.56 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50	Asthma	493	7.00 00.7	7.7 0/0	0	0.0 04	0.00	00.0	0/ 6. 1	1.1	14.070	71.1	0.1.0	1.20	6.1%	1.25	2.0%	1.43	5.1% 1	.78 8	.5%				
Type 2 diabetes 250.x0, 250.x2 1.86 4.6% 1.86 3.9% 2.17 3.3% 2.40 16.1% 3.92 21.0% 6.74 35.4% 12.41 43.9% 1.50 17.0% 1.5 Other Other 571.0, 11, 2, 3, 5, 6, 9 2.73 9.8% 2.34 8.7% 3.97 12.8% 3.97 6.9% 1.44 5.2% 1.43 5.7% 2.32 13.4% 1.59 19.5% 1.5 1.50 1.5% 1.5 10.5% 1.5 19.5% 1.5 10.5%	Diabetes																	2)) :					
Cirrhosis of alcoholic liver 571.0, 1, 2, 3, 5, 6, 9 2.73 9.8% 2.73 9.1% 3.34 9.6% 3.34 8.7% 3.97 12.8% 3.97 6.9% 1.44 5.2% 1.43 5.7% 2.32 13.4% Callbladder disease 574,575 2.32 13.4% 2.32 13.4% Callbladder disease 574,575 2.32 13.6% 1.59 19.5% 1.5 0steoarthritis 715 715 7.5% 1.58 1.58 1.58 1.58 1.58 1.58 1.58 1.58	Type 2 diabetes Other	250.x0, 250.x2				1.8(5 4.6%	1.86	3.9%	2.17	6.7%	2.17	3.3%	2.40 1	6.1%	3.92 2	1.0%	6.74 3.	5.4% 12	.41 43	.9% 1	.50 17	. %0.2	.50 1	9.2%
Callbladder disease 574, 575 Callbladder disease 575 Callbadder disease 5 Callbadder disease 575 Callbadder di 575 Callbadder	Cirrhosis of alcoholic liver	571.0, .1, .2,.3,.5,.6,.9	2.73 9.8	3% 2.7	3 9.1	% 3.34	t 9.6%	3.34	8.7%	3.97	12.8%	3.97	6.9%								;				
Chronic barrier 20-224	Gallbladder disease Octeoarthritis	574, 575 715												2 76 3	%b 2	1.44 1.80 1	5.2% 3.5%	1.43	5.7% 2	.32 13 96 9	.4%	50 10	. %2 6	59 2	1 9%
	Chronic back pain	720-724												1.59 1	4.3%	1.59 1	0.3%	2.81 16	8.8% 2	.81 16	.4%	2	2	j 1	2

Table 1

number of cigarettes smoked per day.23 All current smokers who identified themselves as occasional smokers were included in the "light" smoking category. Third, physically inactive individuals were those categorized in the CCHS as "inactive."

We made one adjustment to these base CCHS data, namely estimating the rates of overweight, obesity and physical inactivity for children aged less than 12 years based on the sex-specific rates for 12-14 year olds in the CCHS. We assumed no smoking occurs in children younger than 12 years of age.

Multiple exposure levels

The most basic version of a PAF calculation, derived from the prevalence of a single RF and the RR of a related disease, uses the formula (E(RR-1)) / (E(RR-1)+1)), where E is the proportion of the population exposed to the factor of interest and RR is the relative risk of disease developing in the group exposed to the factor.

More sophisticated approaches are required to calculate PAF when a polytomous RF is involved.²⁴ This is the case for both the excess weight and the tobacco smoking RFs in the current model. Overweight and obesity should be conceived as a trichotomous exposure to excess body weight; i.e., 1) no excess weight, 2) intermediate excess or overweight (prevalence E_{ow}), and 3) more extreme excess or obesity (prevalence E_{OB}). The PAF calculation is as follows:

 $(E_{OW}(RR_{OW}-1) + E_{OB}(RR_{OB}-1)) /$ $(E_{OW}(RR_{OW}-1) + E_{OB}(RR_{OB}-1) + 1))$

Tobacco smoking, on the other hand, should be conceived as a tetrachotomous exposure; i.e., 1) non-smoker, 2) light smoker (prevalence E_{TSI}), 3) moderate smoker (prevalence $\mathrm{E}_{_{TSM}}$), and 4) heavy smoker (prevalence E_{TSH}). The PAF calculation is as follows:

$$\begin{array}{l} (\mathrm{E_{TSL}}(\mathrm{RR_{TSL}}-1) + \mathrm{E_{TSM}}(\mathrm{RR_{TSM}}-1) + \\ \mathrm{E_{TSH}}(\mathrm{RR_{TSH}}-1)) \ / \ (\mathrm{E_{TSL}}(\mathrm{RR_{TSL}}-1) + \\ \mathrm{E_{TSM}}(\mathrm{RR_{TSM}}-1) + \mathrm{E_{TSH}}(\mathrm{RR_{TSH}}-1) + 1)) \end{array}$$

Calculating and adjusting costs

We estimated the economic burden using a prevalence-based cost-of-illness approach, and reported this in 2012 Canadian dollars. We began calculating direct costs using the approach adopted by Anis et al.¹¹ In short, direct costs, including hospital care, physician services, other health care professionals (but excluding dental services), drugs, health research and "other" health

 Table 2.
 Estimated prevalence of RFs, total economic burden for multifactorial system, and disaggregated costs by RF

 Canada, 2012, by sex, adjusted for multiple RFs in one individual

	% Population with RF	# Individuals with RF	Direct cost per individual with RF (\$'s)	Indirect cost per individual with RF (\$'s)	Total cost per individual with RF (\$'s)	Total direct cost of RF (million\$)	Total indirect cost of RF (million\$)	Total cost of RF (million\$)
Males			(+ -)	(+ -)	(+ -)	((
Smokers								
Light	8.3%	1,435,035	\$767	\$1,598	\$2,365	\$1,100	\$2,294	\$3,394
Moderate	5.9%	1,024,846	\$1,279	\$2,669	\$3,948	\$1,311	\$2,735	\$4,046
Heavy	6.5%	1,129,249	\$1,598	\$3,283	\$4,881	\$1,805	\$3,707	\$5,512
Subtotal - Male Smokers	20.7%	3,589,130	\$1,175	\$2,434	\$3,609	\$4,216	\$8,736	\$12,952
Excess Weight								
Overweight	34.7%	6,046,660	\$156	\$468	\$624	\$945	\$2,827	\$3,772
Obese	16.0%	2,773,601	\$565	\$1,384	\$1,949	\$1,567	\$3,838	\$5,406
Subtotal - Male Excess Weight	50.7%	8,820,261	\$285	\$756	\$1,041	\$2,513	\$6,665	\$9,178
Inactive	41.1%	7,149,313	\$195	\$422	\$618	\$1,397	\$3,020	\$4,417
Subtotal						\$8,125	\$18,422	\$26,547
Females								
Smokers								
Light	7.0%	1.227.115	\$681	\$1.366	\$2.047	\$836	\$1.676	\$2.512
Moderate	5.0%	867,893	\$1,144	\$2,315	\$3,459	\$992	\$2,009	\$3,002
Heavy	3.0%	530,887	\$1,753	\$3,562	\$5,315	\$930	\$1,891	\$2,822
Subtotal - Female Smokers	15.0%	2.625.894	\$1,051	\$2,124	\$3,174	\$2,759	\$5,577	\$8,336
Excess Weight		,,	. ,	. ,				,
Overweight	22.5%	3,987,187	\$256	\$685	\$940	\$1,020	\$2,730	\$3,750
Obesity	12.8%	2.258.665	\$842	\$1,863	\$2,705	\$1,901	\$4,209	\$6,109
Subtotal - Female Excess Weight	t 35.3%	6.245.852	\$468	\$1,111	\$1,579	\$2,921	\$6,939	\$9,859
Inactive	47.5%	8,409,362	\$191	\$472	\$663	\$1,603	\$3,968	\$5,571
Subtotal						\$7,282	\$16,484	\$23,766
Both Sexes								
Smokers	7 (0)	2 ((2 1 (2	* 7 0 7	¢1 401	¢2.210	¢1.02.4	¢2.070	* • • • • •
Light	7.6%	2,662,149	\$/2/	\$1,491	\$2,218	\$1,936	\$3,970	\$5,906
Moderate	5.4%	1,892,739	\$1,217	\$2,507	\$3,/24	\$2,303	\$4,/44	\$7,048
Heavy	4.8%	1,660,137	\$1,648	\$3,3/2	\$5,020	\$2,735	\$5,599	\$8,334
Subtotal - Smokers	17.9%	6,215,024	\$1,122	\$2,303	\$3,425	\$6,974	\$14,313	\$21,288
Excess Weight	aa <i>i</i> a <i>i</i>	4 4 4 4 4 4 4 4 4	***		* 7 5 0	** ***	A	47 500
Overweight	28.6%	10,033,847	\$196	\$554	\$/50	\$1,965	\$5,55/	\$7,522
Obesity	14.4%	5,032,267	\$689	\$1,599	\$2,288	\$3,468	\$8,047	\$11,515
Subtotal - Excess Weight	42.9%	15,066,113	\$361	\$903	\$1,264	\$5,433	\$13,604	\$19,037
Inactive	44.3%	15,558,675	\$193	\$449	\$642	\$3,000	\$6,988	\$9,988
Total						\$15,408	\$34,906	\$50,313
PE - Dick factor								

care expenditures were extracted from the National Health Expenditure Database for Canada.²⁵ All costs (except hospital care) were allocated to each of the co-morbidity categories based on weights published in the Economic Burden of Illness in Canada (EBIC) for 1998.26 Hospital costs were allocated to each co-morbidity based on the proportion of total patient bed-days (based on data from the Canadian Institute for Health Information (CIHI) Hospital Morbidity Database 2000/200127) used in treating patients in Canada with that co-morbidity. Estimated total direct costs were distributed between males and females based on the proportion of hospital bed-days in 2000/2001 utilized by males and females for each of the co-morbidities. Finally, the Canadian sex-specific costs by co-morbidity were multiplied by the calculated sex- and comorbidity-specific PAF. We calculated indirect costs (premature mortality, short- and long-term disability) following the method used in EBIC, 1998 (a modified human-capital approach).

Economic benefits of risk factor reduction

A number of key assumptions were made in modelling the economic benefits associated with future RF reduction in the Canadian population. First, population projections for the 20-year timeframe from 2012 to 2031 by sex and five-year age group were based on projections by Statistics Canada.²⁸ Second, RF prevalence by sex and five-year age group was calculated for 2010 using the CCHS 2010 Public Use Microdata File.²³ Third, the base model uses

e72 REVUE CANADIENNE DE SANTÉ PUBLIQUE • VOL. 105, NO. 1

a constant 1% relative annual reduction in the RFs of tobacco smoking, physical inactivity and excess weight. Current trends of decreasing smoking prevalence and increasing weight and inactivity are not factored into the model. Fourth, constant 2012 dollars are used throughout the modelling process (i.e., no adjustments are made for projected inflation) in order to clearly identify changes in the economic burden associated with changing RF prevalence, rather than confusing these results with inflationary increases. Fifth, obese individuals move into the overweight category while overweight individuals move into the healthy weight category. Sixth, the benefits associated with physical activity and moving to a healthier weight accrue within a year.²⁹ Last, the benefits of smoking cessation accrue over time, as per Figure 1.³⁰

RESULTS

Table 1 shows the fully adjusted prevalence of RF exposure, the statistically significant RR data by sex and the calculated PAF of disease incidence related to each RF. The PAF for all co-morbidities, with the obvious exception of gynecological and breast cancers, vary by sex. This type of detailed analysis has important implications in determining direct and indirect costs.

Table 2 includes a summary of the adjusted estimates of the prevalence of the chronic disease RFs, the absolute numbers of Canadians with each RF and the fully adjusted economic results. The total annual economic burden in Canada attributable to

Figure 2. Estimated direct and indirect economic burden of smoking, excess weight and physical inactivity, Canada, 2012 (\$000,000), adjusted for multiple risk factors in one individual



S-T = Short-term; L-T = Long-term.





S-T = Short-term; L-T = Long-term.

The s Trojected fish factor prevalence, canada, 2012 compared with 2051 (no change) & 2051 (170 reduction	Table 3.	Projected risk factor prevalence	, Canada, 2012 compared with 2031 (no change) & 2031 (1% reduction
--	----------	----------------------------------	-------------------------------------	---------------------------------

	20	12	2031 (N a	Change)	2031 (1%	Reduction)
	% Population with RF	# Individuals with RF	% Population with RF	# Individuals with RF	% Population with RF	# Individuals with RF
Males						
Smokers						
Light	8.3%	1,435,035	7.6%	1,594,064	6.3%	1,305,506
Moderate	5.9%	1.024.846	5.6%	1,159,318	4.6%	950,121
Heavy	6.5%	1,129,249	6.1%	1,263,547	5.0%	1.033.028
Subtotal - Male Smokers	20.7%	3,589,130	19.3%	4.016.929	15.8%	3,288,655
Excess Weight		-,,		, , .		-, -,
Overweight	34.7%	6.046.660	35.0%	7.306.670	31.7%	6.605.100
Obese	16.0%	2.773.601	15.6%	3,258,843	12.9%	2.679.466
Subtotal - Male Excess Weight	50.7%	8.820.261	50.7%	10.565.513	44.5%	9,284,567
Inactive	41.1%	7.149.313	41.6%	8.683.597	34.5%	7.183.620
Subtotal		.,,		-,,		.,,.
Females						
Smokers						
Light	7.0%	1,227,115	6.5%	1,372,665	5.3%	1,124,630
Moderate	5.0%	867,893	4.7%	994,982	3.8%	816,662
Heavy	3.0%	530,887	2.9%	611,023	2.4%	501,892
Subtotal - Female Smokers	15.0%	2,625,894	14.0%	2,978,670	11.5%	2,443,184
Excess Weight						
Overweight	22.5%	3,987,187	23.7%	4,927,711	21.9%	4,556,455
Obesity	12.8%	2,258,665	13.2%	2,754,174	10.9%	2,271,475
Subtotal - Female Excess Weight	35.3%	6,245,852	36.9%	7,681,885	32.8%	6,827,931
Inactive	47.5%	8,409,362	48.8%	10,358,354	40.4%	8,585,838
Both Sexes						
Smokers						
Light	7.6%	2,662,149	7.0%	2,966,729	5.8%	2,430,136
Moderate	5.4%	1,892,739	5.1%	2,154,300	4.2%	1,766,783
Heavy	4.8%	1,660,137	4.5%	1,874,569	3.6%	1,534,920
Subtotal - Smokers	17.9%	6,215,024	16.6%	6,995,599	13.6%	5,731,839
Excess Weight						
Overweight	28.6%	10,033,847	29.4%	12,234,381	26.8%	11,161,556
Obesity _	14.4%	5,032,267	14.4%	6,013,017	11.9%	4,950,942
Subtotal - Excess Weight	42.9%	15,066,113	43.8%	18,247,398	38.7%	16,112,497
Inactive	44.3%	15,558,675	45.2%	19,041,951	37.5%	15,769,458

these RFs is \$50.3 billion (\$15.4/\$34.9 billion in direct/indirect costs).

Figure 2 represents the RF-specific burden graphically, with additional information on the components that constitute the indirect costs. The indirect burden related to premature mortality dominates as an outcome of tobacco smoking (\$9.7 billion, or 68% of \$14.3 billion in total indirect costs for that RF) and is also marginally higher than disability in the case of physical inactivity. The reverse is true for excess weight, where the economic burden of disability (\$8.1 billion) outstrips the costs of premature mortality (\$5.5 billion).

This analysis indicates that the disaggregated economic burden for excess weight in Canada in 2012 at \$19.0 billion remains lower than the economic burden related to tobacco smoking at \$21.3 billion.

It appears that cardiovascular diseases tend to dominate the disease burden that is attributable to these RFs. Of the \$50.3 billion in annual economic burden, \$21.0 billion (41.8%) is associated with cardiovascular diseases, \$9.8 billion (19.4%) with cancers, \$9.3 billion (18.5%) with musculoskeletal diseases, \$6.6 billion (13.2%) with respiratory diseases and \$3.2 billion (6.4%) with diabetes (see Figure 3).

Table 3 provides a summary of the estimated number of individuals in Canada with the RFs in 2012 and compares them to 2031 with either an assumption of no change or a 1% relative annual reduction in RF prevalence. With a 1% reduction, the proportion of Canadians who smoke would decrease from 17.9% in 2012 to 13.6% in 2031. In terms of absolute numbers of Canadians who smoke, the decrease would be from 6.2 million in 2012 to 5.7 million in 2031. The proportion of Canadians with excess

weight would decrease from 42.9% to 38.7% while the proportion of physically inactive Canadians would decrease from 44.3% to 37.5%.

The economic burden associated with these RFs in Canada would increase from \$50.3 billion in 2012 to \$59.2 billion in 2031 (in constant 2012 dollars), assuming no change in RF prevalence, i.e., based solely on population growth (see Table 4). A 1% relative annual reduction in each of the three RFs would result in this projected economic burden of \$59.2 billion decreasing to \$50.8 billion (-\$8.5 billion) in 2031. This reduction consists of \$3.2, \$3.1 and \$2.1 billion, respectively, for decreases in excess weight, tobacco smoking and physical inactivity (see Figure 4). Over the 20-year period from 2012 to 2031, a 1% relative annual reduction in economic burden of \$78.0 billion (consisting of \$31.2, \$26.4 and \$20.3 billion, respectively, for decreases in excess weight, tobacco smoking and physical inactivity).

Sensitivity analysis

The point estimates for RR are used in the base model results presented above. We used the lower and upper bounds of the 95% CI for the RR associated with each RF and disease in a sensitivity analysis. Using the lower bounds resulted in a decrease in the total estimated economic burden in 2012 from \$50.3 billion to \$41.6 billion (or -17.3%) while applying the upper bounds increased the total economic burden to \$58.7 billion in 2012 (or +16.7%) (see Table 5).

DISCUSSION

The annual economic burden of the RFs of tobacco smoking, excess weight and physical inactivity in Canada are estimated at

 Table 4.
 Projected economic burden of smoking, excess weight and physical inactivity, Canada, 2012 compared with 2031 (no change) & 2031 (1% reduction), 2012 constant dollars

		2012		203	1 (No Chan	ge)	203 1	(1% Reduc	tion)
	Total direct cost of RF (M\$'s)	Total indirect cost of RF (M\$'s)	Total cost of RF (M\$'s)	Total direct cost of RF (M\$'s)	Total indirect cost of RF (M\$'s)	Total cost of RF (M\$'s)	Total direct cost of RF (M\$'s)	Total indirect cost of RF (M\$'s)	Total cost of RF (M\$'s)
Males									
Smokers	¢1 100	¢2.204	¢2 204	¢1 222	¢ 2 5 40	¢0.770	¢1.050	¢0.011	¢2.240
Light	\$1,100	\$2,294	\$3,394	\$1,222	\$2,548	\$3,770	\$1,058	\$2,211	\$3,269
Moderate	\$1,311	\$2,735	\$4,046	\$1,483	\$3,094	\$4,5//	\$1,285	\$2,686	\$3,971
Heavy	\$1,805	\$3,707	\$5,512	\$2,019	\$4,148	\$6,168	\$1,746	\$3,596	\$5,342
Subtotal - Male Smokers	\$4,216	\$8,736	\$12,952	\$4,724	\$9,790	\$14,515	\$4,089	\$8,493	\$12,582
Excess Weight	¢045	¢0.007	¢0 770	¢1 1 4 3	¢2 41 C	¢ 4 5 5 0	¢1 022	¢2,000	¢ 4 1 0 1
Overweight	\$945	\$2,827	\$3,//2	\$1,142	\$3,416	\$4,558	\$1,033	\$3,088	\$4,121
Obese Subtatal Mala Europa Wainht	\$1,507	\$3,838 \$6,665	\$5,400	\$1,842	\$4,510	\$0,332 \$10,010	\$1,514	\$3,708	\$3,ZZZ
Subtotal - Male Excess Weight	\$2,513	\$6,665	\$9,178	\$2,984	\$7,926	\$10,910	\$2,547	\$6,796	\$9,343
Inactive	\$1,397 ¢0125	\$3,020	\$4,417 \$26.547	\$1,090	\$3,009 \$31,205	\$3,303 \$30,700	\$1,403	\$3,035 ¢10,234	\$4,438 \$26,262
Subtotal	\$0,123	\$10,422	\$20,347	\$9,403	\$21,303	\$30,769	\$0,039	\$10,524	\$20,303
Females									
Smokers									
Light	\$836	\$1,676	\$2,512	\$935	\$1,875	\$2,810	\$814	\$1,634	\$2,448
Moderate	\$992	\$2,009	\$3,002	\$1,138	\$2,303	\$3,441	\$992	\$2,010	\$3,002
Heavy	\$930	\$1,891	\$2,822	\$1,071	\$2,177	\$3,248	\$934	\$1,901	\$2,835
Subtotal - Female Smokers	\$2,759	\$5,577	\$8,336	\$3,144	\$6,356	\$9,499	\$2,740	\$5,544	\$8,285
Excess Weight									
Overweight	\$1,020	\$2,730	\$3,750	\$1,261	\$3,374	\$4,634	\$1,166	\$3,120	\$4,285
Obesity	\$1,901	\$4,209	\$6,109	\$2,318	\$5,132	\$7,450	\$1,912	\$4,233	\$6,144
Subtotal - Female Excess Weight	\$2,921	\$6,939	\$9,859	\$3,578	\$8,506	\$12,084	\$3,077	\$7,352	\$10,429
Inactive	\$1,603	\$3,968	\$5,571	\$1,975	\$4,888	\$6,862	\$1,637	\$4,051	\$5,688
Subtotal	\$7,282	\$16,484	\$23,766	\$8,697	\$19,749	\$28,446	\$7,454	\$16,948	\$24,402
Both Sexes									
Smokers									
Light	\$1,936	\$3,970	\$5,906	\$2,157	\$4,423	\$6,580	\$1,872	\$3,845	\$5,717
Moderate	\$2,303	\$4,744	\$7,048	\$2,621	\$5,397	\$8,018	\$2,277	\$4,696	\$6,973
Heavy	\$2,735	\$5,599	\$8,334	\$3,090	\$6,325	\$9,416	\$2,681	\$5,496	\$8,177
Subtotal - Smokers	\$6,974	\$14,313	\$21,288	\$7,868	\$16,146	\$24,014	\$6,829	\$14,038	\$20,867
Excess Weight									
Overweight	\$1,965	\$5,557	\$7,522	\$2,403	\$6,790	\$9,193	\$2,198	\$6,208	\$8,406
Obesity	\$3,468	\$8,047	\$11,515	\$4,159	\$9,642	\$13,801	\$3,426	\$7,941	\$11,367
Subtotal - Excess Weight	\$5,433	\$13,604	\$19,037	\$6,562	\$16,432	\$22,994	\$5,624	\$14,148	\$19,772
Inactive	\$3,000	\$6,988	\$9,988	\$3,671	\$8,556	\$12,227	\$3,040	\$7,086	\$10,126
Total	\$15,408	\$34,906	\$50,313	\$18,101	\$41,134	\$59,235	\$15,493	\$35,272	\$50,765
DE Diel fastan									

RF = Risk factor.

\$50.3 billion in 2012 (\$15.4/\$34.9 billion in direct/indirect costs). Of this amount, \$21.3 billion is attributable to tobacco smoking (\$7.0/\$14.3 billion in direct/indirect costs), \$19.0 billion is attributable to excess weight (\$5.4/\$13.6 billion in direct/indirect costs), and \$10.0 billion is attributable to physical inactivity (\$3.0/\$7.0 billion in direct/indirect costs).

Total health care expenditures in Canada in 2012 are estimated at \$207.4 billion.²⁵ The total direct health care costs attributable to tobacco smoking, excess weight and physical inactivity of \$15.4 billion represents 7.4% of this total. Kaiserman estimated smoking attributable health care costs in Canada in 1991 to be \$2.5 billion,¹² or about 3.8% of the \$66.3 billion total health care costs in Canada that year.25 Similarly, Rehm and colleagues estimated smoking attributable health care costs in Canada in 2002 to be \$4.4 billion,³¹ or 3.8% of the \$115.1 billion total health care costs in Canada that year.25 Our finding of 3.4% (\$7.0 of \$207.4 billion) may be at least partially attributable to a reduction in smoking prevalence from 25.9% to 19.9% of the population aged 12 and over in Canada during the last decade³² as well as adjustments made to avoid double counting. Katzmarzyck and Janssen estimated the direct health care costs attributable to physical inactivity and obesity to be \$1.6 billion each in 2001,9 or 1.5% of the \$107.2 billion total health care costs in Canada that year.²⁵ Our estimate of 2.6% for excess weight includes both overweight and obesity. Including just obesity would reduce direct

care costs to 1.7% (\$3.5 of \$207.4 billion), or slightly higher than the 1.5% estimated by Katzmarzyck and Janssen. Anis and colleagues estimated the combined direct costs of overweight and obesity in Canada in 2006 to be \$6.0 billion, or 4.0% of the \$150.8 billion total health care costs in Canada that year.²⁵ Of the \$6.0 billion, approximately \$4.0 billion (or 2.6% of \$150.8 billion) is attributable to obesity. Our estimate of 1.4% (\$3.0 billion of \$207.4 billion) attributable to physical inactivity is somewhat lower than previous estimates of 1.5%.9 Lower estimates of the direct costs attributable to tobacco smoking, excess weight and physical inactivity observed in the current study compared with previous Canadian studies may be at least partially due to addressing double counting when assessing the economic impact of multiple RFs within the population. In addressing double counting, the aggregate economic burden was 13.4% lower than the total that would be generated by crude summation of costs generated by each of the three RFs.

Another important result, generated by having access to sexspecific RF prevalence and RR data, is the difference between males and females in contributing to the total economic burden. Of the \$50.3 billion, \$26.5 billion (52.8%) is attributable to males and \$23.8 billion to females. The costs associated with tobacco smoking, however, are higher for males (\$13.0 billion) than for females (\$8.3 billion), which is a reflection of the continuing higher prevalence of tobacco smoking among men (20.7% vs. 15.0%

Figure 4. Changes in economic burden of smoking, excess weight and physical inactivity, 1% reduction in risk factor prevalence compared to no reduction, Canada, 2012-2031 (constant million \$)



among women) and the fact that a higher proportion of men are heavy smokers (6.5% vs. 3.0%). The overall sex-specific distribution for the burden of key modifiable RFs has important implications for prevention planning and public health messaging.

Our analysis suggests that even a modest 1% annual relative reduction in the RFs of tobacco smoking, excess weight and physical inactivity can have a substantial health and economic impact over time at the population level. Indeed, such a change could bend the cost curve over a 20-year period to the point where the economic burden associated with these RFs would remain essentially constant despite the projected growth in Canada's population from 33 million in 2012 to 42 million in 2031.

The analysis of the economic burden related to the RF system and the individual RFs is the first phase of any attempt to project the potential economic impact of applying known primary prevention initiatives. A key question is whether a 1% annual relative reduction in these RFs, as assumed in the current analysis, is achievable over the long term. Between 2001 and 2011, smoking rates in Canada fell from 25.9% to 19.9% for the population aged 12 and over³² (a 2.6% relative annual reduction). There are also a number of promising approaches worldwide which include addressing the RFs of excess weight and physical inactivity,³³ such as the experience in North Karelia, Finland.^{34,35}

The quality of the results derived from a PAF analysis is inevitably limited by the quality of the inputs, specifically RR and prevalence data. A potential weakness in this study is the lack of RR information based on Canadian data. A sensitivity analysis using the 95% CI associated with each RR indicates the importance of using robust and accurate RR estimates. The economic modelling also uses older data from CIHI and the *EBIC* for cost allocation purposes, requiring the assumption that the distribution of costs have not changed significantly for specific cost categories over time. Similarly, the method of scaling up from direct costs to indirect costs depends on the assumption that the ratios of costs between different co-morbidities are the same for direct and indirect costs.

REFERENCES

- Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013;368(4):341-50.
- Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st century hazards of smoking and benefits of stopping: A prospective study of one million women in the UK. *Lancet* 2013;381(9861):133-41.
- Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380(9859):2224-60.
- Schroeder SA. New evidence that cigarette smoking remains the most important health hazard. N Engl J Med 2013;368(4):389-90.
- Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. *N Engl J Med* 2013;368(4):351-64.
- Gotay CC, Katzmarzyk PT, Janssen I, Dawson MY, Aminoltejari K, Bartley NL. Updating the Canadian obesity maps: An epidemic in progress. Can J Public Health 2013;104(1):e64-e68.
- Withrow D, Alter DA. The economic burden of obesity worldwide: A systematic review of the direct costs of obesity. *Obes Rev* 2011;12(2):131-41.
- Katzmarzyk PT, Gledhill N, Shephard RJ. The economic burden of physical inactivity in Canada. CMAJ 2000;163(11):1435-40.

 Table 5.
 Estimated total economic burden for multifactorial system, and disaggregated costs by RF, Canada, 2012, by sex, sensitivity analysis (\$Millions)

	Best Estimate of RR	Low Estimate of RR	Variance	% Var.	High Estimate of RR	Variance	% Var.
Males							
Smokers							
Light	\$3,394	\$3,014	-\$380	-11.2%	\$3,770	\$376	11.1%
Moderate	\$4,046	\$3,908	-\$138	-3.4%	\$4,177	\$131	3.2%
Heavy	\$5,512	\$5,259	-\$253	-4.6%	\$5,762	\$250	4.5%
Subtotal - Male Smokers	\$12,952	\$12,181	-\$771	-5.9%	\$13,710	\$758	5.8%
Excess Weight							
Overweight	\$3,772	\$2,718	-\$1,054	-27.9%	\$4,671	\$898	23.8%
Obese	\$5,406	\$3,919	-\$1,487	-27.5%	\$6,850	\$1,445	26.7%
Subtotal - Male Excess Weight	\$9,178	\$6,638	-\$2,541	-27.7%	\$11,521	\$2,343	25.5%
Inactive	\$4,417	\$3,504	-\$913	-20.7%	\$5,309	\$892	20.2%
Subtotal	\$26,547	\$22,323	(\$4,224)	-15.9%	\$30,540	\$3,993	15.0%
Females							
Smokers	AA 54A	** • • • • •	***		A A - A A	****	44.00/
Light	\$2,512	\$2,234	-\$2/8	-11.1%	\$2,794	\$282	11.2%
Moderate	\$3,002	\$2,874	-\$128	-4.3%	\$3,129	\$128	4.3%
Heavy	\$2,822	\$2,677	-\$145	-5.1%	\$2,975	\$154	5.4%
Subtotal - Female Smokers	\$8,336	\$7,785	-2221	-6.6%	\$8,899	\$203	6.8%
Excess Weight	¢2.750	¢2 (0(¢1.074	20 40/	¢ 4 757	¢1 000	26.00/
Oberweight	\$5,730 \$6,100	\$2,000 \$4,500	-\$1,004 ¢1,500	-20.4%	\$4,/3/ ¢7.766	\$1,000 ¢1.657	20.9%
Subtotal Formale Excess Weight	\$0,109 \$0,850	\$4,320 \$7.206	-\$1,309 \$3,652	-20.0%	¢12524	\$1,037 \$2,665	27.1%
Inactive	\$7,0J7 \$5 571	\$7,200	-\$2,033 \$1,260	-20.9%	\$12,324	\$2,003 \$1.161	27.0%
Inactive	\$3,37 I	\$ 4 ,51∠	-\$1,200	-22.0%	\$0,733	\$1,104	20.9%
Subtotal	\$23,766	\$19,303	(\$4,463)	-18.8%	\$28,158	\$4,392	18.5%
Both Sexes							
Jight	\$5.006	\$5 719	\$ 6 5 9	11 104	\$6561	\$ 6 5 9	11 104
Moderate	\$3,900	\$3,240 \$6,782	-\$030 \$265	-11.170	\$0,304	\$030 \$250	3 70%
Home	\$2,040	\$7,02	\$308	-3.870	\$7,507	\$239	1 80%
Subtotal - Smokers	\$21 288	\$19,956	_\$1 321	-6.2%	\$22,609	\$1 221	6.2%
Excess Weight	\$21,200	\$1 <i>2,2</i> 00	-91,521	-0.270	\$22,007	\$1,JZ1	0.270
Overweight	\$7 522	\$5 405	-\$2117	-28.1%	\$9 428	\$1 906	25 3%
Obesity	\$11 515	\$8 439	-\$3,076	-26.7%	\$14 617	\$3 101	26.9%
Subtotal - Excess Weight	\$19.037	\$13,844	-\$5,193	-27.3%	\$24 045	\$5,007	26.3%
Inactive	\$9.988	\$7.816	-\$2172	-21 7%	\$12,045	\$2,057	20.5%
Teel	\$2,200	\$1,010	(*0 (07)	17.20/	\$12,013	\$2,00, \$0,005	1 4 70/
ΙΟΤΑΙ	\$50,313	\$41,626	(\$8,687)	-17.3%	\$58,698	\$8,385	16.7%

RF = Risk factor; RR = Relative risk.

9. Katzmarzyk PT, Janssen I. The economic costs associated with physical inactivity and obesity in Canada: An update. *Can J Appl Physiol* 2004;29(1):90-115.

- Birmingham CL, Muller JL, Palepu A, Spinelli JJ, Anis AH. The cost of obesity in Canada. CMAJ 1999;160(4):483-88.
- Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: An updated cost-of-illness study. *Obes Rev* 2010;11(1):31-40.
- 12. Kaiserman MJ. The cost of smoking in Canada, 1991. Chronic Dis Can 1997;18(1):13-19.
- Moffatt E, Shack LG, Petz GJ, Sauvé JK, Hayward K, Colman R. The cost of obesity and overweight in 2005: A case study of Alberta, Canada. *Can J Public Health* 201;102(2):144-48.
- Janssen I, Lam M, Katzmarzyk PT. Influence of overweight and obesity on physician costs in adolescents and adults in Ontario, Canada. Obes Rev 2009;10(1):51-57.
- Klein-Geltink JE, Choi BC, Fry RN. Multiple exposures to smoking, alcohol, physical inactivity and overweight: Prevalences according to the Canadian Community Health Survey Cycle 1.1. *Chronic Dis Can* 2006;27(1):25-33.
- Krueger H, Williams D, Ready AE, Trenaman L, Turner D. Improved estimation of the health and economic burden of chronic disease risk factors in Manitoba, Canada. *Chronic Dis Inj Can* 2013;33(4):236-46.
- Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. *BMC Public Health* 2009;9:88.
- Wendel-Vos GC, Schuit AJ, Feskens EJ, Boshuizen HC, Verschuren WM, Saris WH, et al. Physical activity and stroke. A meta-analysis of observational data. *Int J Epidemiol* 2004;33(4):787-98.
- 19. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: A meta-analysis. *Br J Cancer* 2009;100(4):611-16.
- 20. Harriss DJ, Atkinson G, George K, Cable NT, Reilly T, Haboubi N, et al. Lifestyle factors and colorectal cancer risk (1): Systematic review and meta-analysis of associations with body mass index. *Colorectal Dis* 2009;11(6):547-63.
- 21. Walter SD. Local estimates of population attributable risk. *J Clin Epidemiol* 2010;63(1):85-93.
- Cole T, Bellizzi M, Flegal K, Dietz W. Establishing a standard definition for child overweight and obesity worldwide: International survey. *BMJ* 2000;320(7244):1240-43.

- 23. Canadian Community Health Survey 2010 Public Use Microdata file on CD-ROM (Catalogue number 82M0013XCB-2011000). All computations, use and interpretation of these data are entirely that of H. Krueger & Associates Inc.
- 24. Hanley J. A heuristic approach to the formulas for population attributable fraction. *J Epidemiol Community Health* 2001;55(7):508-14.
- Canadian Institute for Health Information. National Health Expenditure Trends, 1975 – 2012. Available at: https://secure.cihi.ca/free_products/ NHEXTrendsReport2012EN.pdf (Accessed August 15, 2013).
- Health Canada. *The Economic Burden of Illness in Canada, 1998.* 2002. Available at: http://publications.gc.ca/collections/Collection/H21-136-1998E.pdf (Accessed August 15, 2013).
- Canadian Institute for Health Information. Hospital Morbidity Database, 2000/01 Tabular Results. Available at: https://secure.cihi.ca/free_products/ HospitalMorbidityTabularReports2000-2001.pdf (Accessed August 15, 2013).
- Statistics Canada. Population Projections for Canada, Provinces and Territories, 2009 to 2036, Catalogue No. 91-520-X, using the medium-growth - historical trends (1981 to 2008) scenario (M1), July 1st. Ottawa, ON: Statistics Canada, 2010.
- 29. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *NEJM* 2001;344(18):1343-50.
- 30. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and smoking cessation in relation to mortality in women. *JAMA* 2008;299(17):2037-47.
- Rehm J, Ballunas D, Brochu S, Fischer B, Gnam W, Patra J, et al. The costs of substance abuse in Canada in 2002: Highlights. Canadian Centre on Substance Abuse. Available at: http://www.ccsa.ca/2006%20CCSA%20 Documents/ccsa-011332-2006.pdf (Accessed May 10, 2013).
- 32. Janz T. Health at a glance: Current smoking trends. Statistics Canada Catalogue no. 82-624-X. Available at: http://www.statcan.gc.ca/pub/82-624-x/2012001/article/11676-eng.htm (Accessed May 10, 2013).
- McLean D, Williams D, Lamont S, Krueger H. Community-based Prevention: Reducing the Risk of Cancer & Chronic Disease. Toronto, ON: University of Toronto Press, 2013.
- Vartiainen E, Laatikainen T, Peltonen M, Juolevi A, Mannisto S, Sundvall J, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. *Int J Epidemiol* 2010;39:504-18.

BENEFITS OF RISK FACTOR REDUCTION IN CANADA

35. Puska P. The North Karelia Project: 30 years successfully preventing chronic disease. *Diabetes Voice* 2008;53:26-29.

Received: June 6, 2013 Accepted: January 28, 2014

RÉSUMÉ

OBJECTIF: Le tabagisme, le surpoids et la sédentarité alourdissent beaucoup le fardeau des maladies évitables au Canada. Nous avons appliqué une démarche élaborée récemment afin d'aborder le problème du double comptage dans l'estimation du fardeau économique actuel combiné de ces trois facteurs de risque et d'estimer les avantages économiques de la réduction à long terme des facteurs de risque au Canada.

MÉTHODE : Notre démarche se fonde sur les fractions attribuables dans la population (FAP) pour estimer le fardeau économique associé aux divers facteurs de risque. Lorsqu'elles étaient disponibles, nous avons utilisé des données sur le risque relatif selon le sexe et des données de prévalence selon l'âge et le sexe pour la modélisation. Le surpoids a été modélisé en tant qu'exposition trichotome (sujet de poids normal, en surpoids, obèse), et le tabagisme, en tant qu'exposition tétrachotome (non-fumeur, fumeur léger, fumeur moyen, grand fumeur). Tous les coûts sont en dollars canadiens constants de 2012.

RÉSULTATS : Le fardeau économique annuel des facteurs de risque du tabagisme, du surpoids et de la sédentarité au Canada est estimé à 50,3 milliards de dollars en 2012. L'analyse de sensibilité suggère un intervalle de 41,6 à 58,7 milliards de dollars pour le fardeau économique. Sur ces 50,3 milliards, 21,3 (20 à 22,6) sont imputables au tabagisme, 19 (13,8 à 24) au surpoids et 10 (7,8 à 12) à la sédentarité. Une baisse annuelle relative de 1 % de chacun des trois facteurs entraînerait une réduction annuelle du fardeau économique de 8,5 milliards de dollars d'ici 2031.

CONCLUSION : Une modique baisse annuelle relative de 1 % dans les facteurs de risque du tabagisme, du surpoids et de la sédentarité peut avoir un impact sanitaire et économique considérable au fil du temps au niveau de la population.

MOTS CLÉS : fardeau économique; fraction attribuable dans la population; facteurs de risque; tabagisme; surpoids; sédentarité